Nature Communications

Fruquintinib plus sintilimab in patients with advanced endometrial cancer with mismatch-repair proficient status: a multicenter, single-arm, phase Ib/II trial

2025-12-21

Full text

DOI https://doi.org/10.1038/s41467-025-67375-3